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Abstract
Mammalian cloning by nuclear transfer from somatic cells has created new opportunities to
generate animal models of genetic diseases in species other than mice. Although genetic mouse
models play a critical role in basic and applied research for numerous diseases, often mouse models
do not adequately reproduce the human disease phenotype. Cystic fibrosis (CF) is one such
disease. Targeted ablation of the cystic fibrosis transmembrane conductance regulator (CFTR)
gene in mice does not adequately replicate spontaneous bacterial infections observed in the human
CF lung. Hence, several laboratories are pursuing alternative animal models of CF in larger species
such as the pig, sheep, rabbits, and ferrets. Our laboratory has focused on developing the ferret as
a CF animal model. Over the past few years, we have investigated several experimental parameters
required for gene targeting and nuclear transfer (NT) cloning in the ferret using somatic cells. In
this review, we will discuss our progress and the hurdles to NT cloning and gene-targeting that
accompany efforts to generate animal models of genetic diseases in species such as the ferret.
Introduction
Until recently, the generation of gene-targeted animal
models has primarily relied upon homologous recombi-
nation following direct introduction of transgenes into
embryonic stem cells (ES cells). While this technique has
been successful for animal modeling in the mouse, it has
thus far proven significantly more difficult in larger spe-
cies. To date, the most exciting and promising research in
transgenesis involves the use of fetal and adult somatic
cells to produce genetically identical animals through
nuclear transplantation [1,2]. Successful production of
cloned animals derived from somatic cells was first dem-
onstrated in sheep [3,4] and has more recently been dem-
onstrated in mice [5], cattle [6], goats [7], pigs [8], cats [9],
rabbits, [10] and mules [11]. Transgenic calves [12], gene-
targeted sheep [13], and α-1,3-galactosyltransferase
knockout pigs [14,15] have also been obtained by nuclear
transfer from somatic cells. These successes have made
animal modeling using nuclear transfer in less-studied
species, such as the ferret, more feasible. Since somatic cell
nuclear donors can be easily maintained in vitro and read-
ily targeted for gene mutations, somatic cell-based
embryo cloning is undoubtedly the future method of
choice for generating genetically modified larger animals.
Two major steps are required to clone genetically defined
animals (Figure 1). First, gene targeting must be achieved
in a somatic cell type appropriate for nuclear cloning, and
karyotypically normal clonal cell lines must be isolated.
Second, the nucleus from the mutant somatic cell must be
used to reprogram enucleated recipient oocytes. The
reconstructed embryos must then be implanted in foster
mothers to generate cloned genetically defined animals.
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CF is a recessive inherited genetic disease in the Caucasian
population, with a frequency of about 1 in 3,000 new-
borns [16]. CF is caused by a defect in an epithelial chlo-
ride channel called the cystic fibrosis transmembrane
conductance regulator (CFTR) [16]. CF patients suffer from
recurrent bacterial infection in the lung, leading to bron-
chiectasis, compromised lung function, and ultimately
death. Substantial efforts have been made to generate
mouse models capable of reproducing the lung pathology
seen in CF patients. However, due to differences in lung
biology between mice and humans, CFTR-deficient and
mutant mice do not develop spontaneous lung disease as
seen in humans [17,18]. This lack of appropriate CF ani-
mal models has hindered progress in the development
and testing of therapies for this disease.
The domestic ferret, Mustela Putorius Furos, has proven to
be an excellent animal model for studying CFTR lung biol-
ogy. Several aspects of ferret lung biology make this spe-
cies an attractive model for CF lung disease. First, in
contrast to mice, the ferret has marked similarities to
humans in terms of lung physiology, airway morphology,
and cell types [19–24]. Second, the expression of CFTR in
the ferret airway epithelium and submucosal glands is
identical to that in humans [25,26]. Third, amino acid
identity between ferret and human nucleotide binding
domain 1 (NBD1) of CFTR is a striking 97% [25], which
is just as high as for non-human primates (96%, Macaca
nemestrina) and is significantly higher than for rodents
(80%, rat and mouse). Fourth, the ferret had been a useful
model for viral and bacterial lung infections seen in
humans [27–32]. Lastly, the ferret, with a gestation period
of 42 days and 6 months to sexual maturity, has obvious
advantages over larger species for animal modeling.
Strategy and Progress in Cloning a CF Ferret
Unlike sheep and cattle, for which NT cloning procedures
are well established, cloning in the ferret presents numer-
ous challenges since experimental parameters for embryo
manipulation have not been defined. Over the past few
years, several of the critical steps required for NT cloning
in the ferret have been established [33–35]. This review
will focus on progress in the various steps highlighted in
Figure 2. Furthermore, we will discuss approaches cur-
rently under investigation to facilitate efficient gene tar-
geting in somatic cells, a process required to ultimately
clone a CF ferret.
In Vitro Culture of Ferret Embryos and Successful 
Production of Offspring from Implanted Embryos
A critical first step toward genetic manipulation in a new
species is defining the parameters required for embryo
culture and adoptive transfer into pseudopregnant recipi-
ent females. Optimal superovulation in the ferret (19.3 ±
0.6 oocytes and/or embryos per female) was achieved by
a combination of hormonal injections, including 100 IU
eCG and 150 IU hCG at 72-hr intervals [33]. This ovula-
tion rate is more than double that induced by mating.
Mating with a male immediately following hCG injection
did not significantly alter the ovulated number of oocytes
and/or embryos, indicating that mating is not required for
superovulation in ferrets. Of embryos harvested at the
one-cell stage, 64.5% and 47.1% developed into blasto-
cysts when cultured in vitro in CZB or TCM-199 plus 10%
fetal bovine serum (FBS) media, respectively. In contrast,
only 17.1% of embryos cultured in vitro in NCSU-23
developed to the blastocyst stage. Both freshly retrieved
and  in vitro cultured embryos from cinnamon coat–
colored parents produced live young when transferred at
the 8-cell stage into albino coat–colored, pseudopregnant
recipients. The percentage of kits delivered relative to
embryos transferred was 61% when freshly retrieved
embryos were used and 32% when in vitro cultured
embryos were used. The most important achievement of
these studies was the successful birth of cinnamon coat–
colored pups from an albino female. These results demon-
strate successful embryo transfer in the ferret and open the
door to animal modeling with this species following
embryo manipulation [33].
Conditions for In Vitro Maturation and Parthenogenetic 
Activation of Ferret Oocytes
One of the most critical and difficult steps in successful
cloning of any species is the reprogramming of oocytes to
General strategy for generating gene-targeted animal models  using somatic cell nuclear cloning Figure 1
General strategy for generating gene-targeted animal models 
using somatic cell nuclear cloning. Two major steps include: 
1) Targeting gene mutations in appropriate somatic cell 
nuclear donor and 2) embryo reconstruction and cloning of 
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divide in the absence of fertilization. Optimization of this
step, termed parthenogenetic activation, is very empirical,
and it varies greatly between species. To increase the yield
of oocytes for NT cloning, ovaries are often harvested and
immature oocytes extracted for use. This method requires
a step involving in vitro maturation (IVM), which must
also be optimized prior to activation. The success of acti-
vation is closely linked to the quality of IVM oocytes. To
this end, we have optimized conditions for in vitro matu-
ration and parthenogenetic activation of ferret haploid
oocytes.
Immature oocytes (cumulus-oocyte complexes) harvested
from ovaries of superovulated ferrets have been evaluated
for in vitro maturation conditions using several types of
media [34]. The optimal media for maturation of ferret
oocytes consisted of TCM-199 containing 10% FBS, 10
IU/ml of eCG, and 5 IU/ml of hCG. In this media, the
maturation rate of ferret oocytes was 72% at 24 hrs of
IVM. Optimization of oocyte activation was evaluated
using both electrical and chemical stimuli individually or
in combination. Treatment with cycloheximide (5 µg/ml,
5 min) and 6-dimethylaminopurine (6-DMAP, 2 mM/ml,
4 h) following electrical stimulation (an alternating cur-
rent pulse of 3 V for 5 secs, followed by one direct current
pulse of 180 V/mm for 30 µsec) resulted in 43% of the
oocytes developing to the blastocyst stage. Such an activa-
tion rate represented a significant improvement over
those obtainable under other tested conditions, including
individual treatment with electrical pulses (10%),
The important steps involved in somatic cell nuclear cloning are shown schematically Figure 2
The important steps involved in somatic cell nuclear cloning are shown schematically. Progress in each of the boxed methodol-
ogies will be discussed in detail in subsequent sections [33–35]. Italicized labels indicate descriptive markings, not methodolog-
ical steps per se.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/83
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cycloheximide (3%), or 6-DMAP (5%). Blastocysts
derived from in vitro activation appeared to be normal
morphologically and were composed of an appropriate
number of both inner cell mass (10.3 ± 1.1) and trophec-
toderm (60.8 ± 2.9) cells when they were examined using
a technique [36] that differentially stains the inner cell
mass (ICM) and trophectoderm (TE) layer [34].
Developmental Capacity of Ferret Embryos by Nuclear 
Transfer Using G0/G1-Stage Fetal Fibroblasts
With the ultimate goal of establishing experimental proto-
cols necessary for cloning ferrets, we have begun to exam-
ine parameters for ferret cloning by nuclear transfer using
G0/G1-stage donor fetal fibroblasts [35]. Cumulus-oocyte
complexes were harvested from ovaries of superovulated
ferrets and cultured in a maturation medium for 24 hrs.
Following removal of cumulus cells, oocytes with normal
morphology, uniform cytoplasm, and a first polar body
were enucleated with a 25 µm (inside diameter, ID) glass
pipette. Critical to successful embryo reconstruction by
nuclear transfer is the complete removal of oocyte chro-
mosomal DNA. Fluorescent DNA dye (such as Hoechst
33342) can be used to practice and evaluate enucleation
efficiencies. However, these stains cannot be used during
cloning since they affect the viability of the reconstructed
embryo. Since the removal of too much of the oocyte
cytoplasm also leads to poor cloning efficiencies, it is crit-
ical that the individual performing the work optimizes
this step. The proportion of completely enucleated ferret
oocytes was 80.8% ± 2.6 (n = 82) in the studies discussed
below.
Following optimization of enucleation procedures, ferret
fetal fibroblast cells (serum-starved for 14–16 hrs prior to
NT) were injected directly into enucleated oocytes with a
10  µm (ID) PiezoDrill glass pipette. Reconstructed
embryos were then activated by a combination of electri-
cal pulses and chemical stimulations. Subsequently, the
reconstructed and activated embryos were either cultured
in vitro or transferred to pseudopregnant ferrets to evaluate
their development capabilities in vitro and in vivo. Our
results demonstrated that 56.3% of reconstructed
embryos cleaved, while 26.0% and 17.6% developed to
morula and blastocyst stages in vitro, respectively [35]. The
blastocysts derived from NT embryos demonstrated nor-
mal morphology by differential staining and also con-
tained cell numbers appropriate for normal blastocysts
developed in vitro. In vivo developmental studies at 21
days post-transplantation demonstrated 8.8% of recon-
structed embryos implanted into the uterine lining of
recipients, while 3.3% formed fetuses (Figure 3). How-
ever, reconstructed embryos failed to develop to term (42
days). These results demonstrate that donor nuclei of G0/
G1-stage fetal fibroblast cells can be reprogrammed to
support the development of reconstructed ferret embryos
in vitro and in vivo [35].
One facet of cloning that has been highly variable
between species is the narrow window of post-mating
uterine development that is receptive for implantation of
NT-reconstructed embryos. These differences are due to
the developmental delay caused by NT reconstruction of
embryos. To solve this problem, researchers have utilized
asynchronous breeding schedules of the oocyte donors
Implantation and fetal development of NT-reconstructed ferret embryos Figure 3
Implantation and fetal development of NT-reconstructed ferret embryos. (A and B) Ovaries, oviducts and the uteri from two 
recipient albino ferrets were dissected at 21 days following transfer of ~25 NT-reconstructed embryos. The swollen regions of 
the uterus (denoted by arrows) are regions of implanted NT-reconstructed embryos. Recipient albino Jills were mated with 
vasectomized (sterile) male albino studs. Vasectomized studs were proven sterile by sperm count and mating. Albino oocytes 
were reconstructed with sable × cinnamon F1 fetal ferret fibroblasts. (C) Fetuses marked 1 and 2 were dissected from the 
swollen regions of the uterus in Panel B. (D) Normal 3-week ferret fetus developed from in vivo fertilization by normal mating. 
Embryo #1 appears to have normal 21-day development and is approximately 1.5 cm on the longest axis. Scale marker: Panels 
A and B, 1.5 cm; Panels C and D, 0.5 cm. Reproduced with permission from a published manuscript by Li et al [35].Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/83
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and the female recipients used for implantation of NT-
reconstructed embryos [10]. Current efforts attempting to
clone ferrets to live birth are optimizing asynchronous
breeding schedules to improve survival in vivo.
Allele-Specific Targeting of Single Base-Pair Changes in 
Somatic Cells with Chimeric RNA/DNA Oligonucleotides
In addition to embryo manipulation procedures in the
ferret, efficient strategies for introducing mutations into
the ferret CFTR gene must be developed in order to gener-
ate appropriate somatic cell donors for NT cloning. Sev-
eral criteria are important when considering the
appropriate targeting strategy for somatic cells. First, the
strategy cannot be dependent on expression of the target
gene (ie., gene targeting using promoter-trapping) since
the CFTR gene is not expressed in fibroblasts. Second,
since low-passage somatic cells are preferred for NT clon-
ing, the targeting strategy should be efficient and opti-
mally not require selective pressure. Third, a highly
sensitive and efficient screening method must be
developed to isolate gene-targeted clonal cell lines at early
passage. One advantage of NT cloning for generating
genetically defined animal models is that theoretically,
relatively few somatic cell donors are required to carry out
the procedure. Hence, we have focused on developing
methods based on nuclear injection of gene-targeting
agents, followed by high-throughput screening of single-
cell clones in 96-well plates for successful gene alterations.
One suitable targeting agent we are currently evaluating
utilizes chimeric RNA/DNA oligonucleotides (also called
chimeraplasts).
To establish our ability to target the CFTR gene and rap-
idly screen large numbers of clonal cell lines, we began
evaluating chimeraplasts in cell systems already estab-
lished to target at high efficiencies. Chimeraplasts are self-
folding RNA/DNA duplexes that create hairpin ends with
flanking homology (10–30 bp) to the target base. Chime-
raplasts have been reported to introduce single base-pair
changes at the β-globin locus at efficiencies between 1 and
5% in Hela cells [37] and as high as 10% in other systems
[38,39]. Since chimeraplasts are most efficient at intro-
ducing single base-pair alterations, we have evaluated the
ability of chimeraplasts to target the G551D mutation to
the CFTR gene that requires only a single-base alteration.
With the ultimate goal of generating ferret fibroblast cell
lines heterozygous for the G551D mutation, we first
sought to develop targeting and screening methodologies
in Hela cells. Since such targeting methods are non-selec-
tive, it is imperative that the targeting efficiency be ≥ 0.1%
so that suitable somatic clones can be identified from a
pool of fewer than 1000 cells.
Initially, we based our chimeraplast design on the original
reports describing this technology [38,39]. The non-cod-
ing strand in the oligonucleotide contains two 10–15-nt
long, 2'-O-methyl RNA stretches, flanking a 5 bp DNA
sequence, with the mutation to be generated in the central
position. A 68-mer chimeric oligonucleotide, shown in
Figure 4a, was synthesized and purified by IDT (Iowa City,
IA) and transfected into Hela cells using standard Lipo-
fectamine (Gibco)-mediated methods. Although direct
nuclear injection was used in similar targeting strategies
for primary ferret fetal fibroblasts, transfection efficiencies
in Hela cells were high enough to work out the methodol-
ogies of screening. The efficiency of transfection, which
was tested with a FITC-labeled oligonucleotide of similar
length, was demonstrated to be >95% (data not shown).
Specifically, 1.8 µg of chimeraplasts were transfected into
50% confluent 5 × 104 Hela cells in 200 µl serum-free
DMEM medium/lipofectamine reagent at RT for 30 min
in a 24-well plate. The cells were allowed to grow to con-
fluence following the addition of 10% FBS. They were
then trypsinized and serially diluted into 96-well plates
for cloning. The cell concentration was determined before
seeding so that only 50% of the wells would lead to the
clonal outgrowth of a single cell. After the wells reached
confluence, approximately 5000 cells were removed by
scraping with a multi-channel pipette. The remaining cells
were fed fresh media and allowed to grow back to conflu-
ence. Harvested cells from each clone were then pelleted
and lysed directly in 60 µl of denaturing buffer containing
500 mM NaOH, 2.0 M NaCl, and 25 mM EDTA. After
boiling for 5 min, 6 µl of 1 M Tris-Cl was added to cell
lysates for neutralization. Nested PCR was then performed
with 6 µl of the neutralized lysates as templates, using the
following primers:
1st  round 5'-ACATTAGAAGGAAGATGTGCC-3'/5'-
GTGCCTTTCAAATTCAGATTGAGC-3'
2nd  round 5'-GGGCACAGATTCTGAGTAACC-3'/5'-
AATGTGATTCTTAACCCACTAGCC-3'
One tenth of each PCR product was loaded onto a Nylon
membrane using a slot-blotting apparatus and screened
for mutations by allele-specific oligonucleotide (ASO)
hybridization. The sequences for the wild-type and
mutant ASO primers were as follows: 1) wild-type, GAGT-
GGAGGTCAACGAG, and 2) G551D mutant, GAGTGGA-
GATCAACGAG. Primers were end-labeled with [γ-32]ATP,
and hybridization was performed overnight in a solution
containing 3 M tetramethylammonium chloride (TMAC),
0.6% SDS, 1 mM EDTA, 10 mM Na3PO4 (pH 6.8), 5 ×
Denhardt, and 40 µg/ml yeast DNA. The blots were
washed in 3 M TMAC, 1 mM EDTA, 10 mM Na3PO4 (pH
6.8), and 0.6% SDS twice at RT, followed by 2 more
washes at 53°C. Membranes were then exposed to film.
Since the G to A mutation leads to the loss of a Hindi
restriction site and a gain of DpnI and DpnII sites, positiveReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/83
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clones detected by ASO were confirmed by restriction
digestion analysis following amplification of genomic
DNA.
Since gene targeting efficiencies were expected to be fairly
low, we initiated this line of research by developing meth-
ods for mutant screening that were amenable to analyzing
1000 cell clones. We settled on using a 96-well plate to
screen crude cell lysates by PCR. These plates could also be
replicated easily by simply scraping cells from one plate
into another without the need for trypsinization. This
approach will be of considerable benefit when applied to
ferret fibroblasts since it requires minimal amplification
of cell clones, and will thus likely increase cellular compe-
tence for NT experiments. A variety of lysis buffers were
tested for efficient amplification of the target by nested
PCR. The lysis buffer discussed above allowed successful
PCR from as few as 1,000 cells. ASO screening of 44 sin-
gle-cell clones generated from chimeraplast-transfected
Hela cells resulted in 3 positive clones that strongly
hybridized to the G551D mutant oligonucleotide (Figure
4b and 4c). Each of these targeted clones demonstrated
the expected restriction site changes caused by a G → A
conversion. In summary, we feel that this preliminary
data has provided the means for rapid effective screening
of targeted primary fibroblasts or any other cell type use-
ful for NT cloning. The 7.6% targeting efficiency for the
human CFTR gene found in this study also suggests that
chimeraplasts may be a useful targeting strategy in the
generation of mutant ferret somatic cells.
Although studies with Hela cells have helped establish the
screening protocols for selecting CFTR-targeted clonal cell
lines, approaches for targeting primary fetal ferret fibrob-
lasts have proven more difficult due to low transfection
efficiencies. To this end, a single-cell injection approach
was adopted in which targeting agents can be injected
directly into the nucleus of primary ferret fibroblasts.
Studies utilizing a mutant EGFP(Y66S) fluorescent recov-
ery assay were established to help define the optimal con-
ditions for gene targeting with chimeraplasts in ferret fetal
fibroblasts [40]. Both episomal mutant EGFP plasmids
and mouse transgenic fetal fibroblasts expressing the
mutant EGFP gene were used as targets for chimeraplasts.
Since the mutant EGFP protein is non-fluorescent, the
simple index of fluorescent recovery could be used to
assess the efficiency of gene targeting. Results from this
study demonstrated that chimeraplasts could efficiently
(~1–2%) target correction of mutant episomal DNA tar-
gets. However, they failed to correct an integrated mutant
EGFP gene in fetal fibroblasts from transgenic mice.
Although these results are disappointing, several advances
in small oligonucleotide targeting may help to improve
the efficiency of this approach. Recent reports have sug-
gested that the polarity of the DNA segment in the
Chimeraplast targeting of the G551D mutation to the human  CFTR gene in Hela cells Figure 4
Chimeraplast targeting of the G551D mutation to the human 
CFTR gene in Hela cells. (A) The 25 bp segment homologous 
to CFTR is bolded, with the mutated nucleotide (G → A) 
indicated by asterisks. This structure is based on the tradi-
tional design with a 5 bp DNA (capitalized and underlined) 
core region flanked by two 10-nt 2'-O-methyl RNA stretches 
(lowercased). Only one base-pair change exists in parenthe-
ses for generating such an oligo for ferret CFTR. (B, C) Cell 
lysates prepared with 44 targeted Hela cell clones after 
G551D chimeric oligonucleotide transfection were amplified 
by 2 rounds of PCR and analyzed by ASO hybridization 
against (B) wild-type CFTR and (C) G551D mutant oligonu-
cleotide probes. Three of these cell clones (2b, 3c, and 6a) 
were highly positive for both the wild-type and the G551D 
genotype, as indicated by the asterisks. Positive plasmid 
cDNA controls for the wild-type (1e) and the G551D (1f) 
CFTR sequences were also run as standards. PCR blanks are 
shown in 1 g and 1 h. All other wells contain experimental 
Hela cell clone PCR material. Wells that showed no hybridi-
zation to either probe probably contained no DNA material, 
which was likely due to insufficient cells for efficient PCR.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/83
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targeting construct affects the efficiency of gene targeting
by more than 1000-fold [41]. We have currently only
tested for base alteration targeted to the antisense strand
of the target gene (i.e., chimeraplast DNA segments
encode the mutation in the sense strand). However, the
alternative design, placing mutations in the anti-sense
strand of the targeting DNA oligonucleotide, has proven
significantly more effective [41]. Such adaptations to the
described approach may be used to increase targeting effi-
ciencies for integrated genes in primary fibroblasts.
Future Challenges in Mammalian Cloning of 
Genetic Disease Models
Mammalian cloning has been accomplished in several
mammalian species by nuclear transfer of somatic cells.
However, widespread use of this technology has been lim-
ited due to low efficiencies of cloning to live births. At
present, cloning efficiency – as determined by the propor-
tion of live offspring developed from all oocytes that
receive donor cell nuclei – is no more than 3%, regardless
of the developmental age of the donor cell or the type of
cell used [42].
The low efficiency associated with cloning may be attrib-
uted to many factors that are not fully understood, such as
the oocyte-donor cell interaction [3], the stage of the
donor cell cycle [4,43–46], the type of donor cell used
[47,48], and inappropriate or incomplete nuclear repro-
gramming following nuclear transfer [49,50]. In addition,
technical skill greatly contributes to the cloning success
rate. Even the slightest damage to the donor cell (cyto-
plasm and/or nucleus) may render the nuclei incapable of
participating in normal embryo development.
Changes in DNA methylation patterns may also account
for the low efficiency of present cloning approaches. DNA
methylation is highly dynamic in cleavage-stage embryos
of a number of mammalian species. Failure to properly
recapitulate pre-implantation DNA methylation patterns
in embryos derived by nuclear transfer may contribute to
the low efficiency of nuclear transfer in producing live off-
spring [49]. It is natural to speculate that oocyte cyto-
plasm has 'special ingredients' that reprogram epigenetic
imprinting from the somatic state to the zygotic state.
Attempts to increase the efficiency of cloning by increas-
ing the exposure time of donor nuclei to the oocyte's cyto-
plasm have met with some, though by no means dramatic
success [45,51–53]. It was also somewhat surprising that
using the so-called 'totipotent' ES cells for cloning was not
as successful as expected [54,55]. However, more recent
studies using out-bred F1 ES cell lines have demonstrated
higher efficiencies in reconstructing oocytes capable of
developing to live-born pups and increasing post-natal
survival [56].
In conclusion, although mammalian cloning is still in its
infancy, it is likely to change the face of animal modeling
in the near future. As new methods for embryo manipula-
tion and NT cloning merge with highly efficient gene tar-
geting approaches, the ability to generate innovative
larger animal models of genetic disease will significantly
increase. Such efforts will greatly benefit the field of
molecular medicine.
Acknowledgments
We gratefully acknowledge the editorial assistance of Leah Williams and 
NIDDK (DK47967/JFE), NHLBI (HL61234/MJW), and CFF research fund-
ing for the author's laboratory in the area of this review.
References
1. Di Berardino MA: Animal cloning – the route to new genomics
in agriculture and medicine. Differentiation 2001, 68:67-83.
2. Renard JP, Zhou Q, LeBourhis D, Chavatte-Palmer P, Hue I, Heyman
Y and Vignon X: Nuclear transfer technologies: between suc-
cesses and doubts. Theriogenology 2002, 57:203-222.
3. Campbell KH, McWhir J, Ritchie WA and Wilmut I: Sheep cloned
by nuclear transfer from a cultured cell line.  Nature 1996,
380:64-66.
4. Wilmut I, Schnieke AE, McWhir J, Kind AJ and Campbell KH: Viable
offspring derived from fetal and adult mammalian cells.
Nature 1997, 385:810-813.
5. Wakayama T, Perry AC, Zuccotti M, Johnson KR and Yanagimachi R:
Full-term development of mice from enucleated oocytes
injected with cumulus cell nuclei. Nature 1998, 394:369-374.
6. Kato Y, Tani T, Sotomaru Y, Kurokawa K, Kato J, Doguchi H, Yasue
H and Tsunoda Y: Eight calves cloned from somatic cells of a
single adult. Science 1998, 282:2095-2098.
7. Baguisi A, Behboodi E, Melican DT, Pollock JS, Destrempes MM, Cam-
muso C, Williams JL, Nims SD, Porter CA and Midura P et al.: Pro-
duction of goats by somatic cell nuclear transfer. Nat Biotechnol
1999, 17:456-461.
8. Polejaeva IA, Chen SH, Vaught TD, Page RL, Mullins J, Ball S, Dai Y,
Boone J, Walker S and Ayares DL et al.: Cloned pigs produced by
nuclear transfer from adult somatic cells.  Nature 2000,
407:86-90.
9. Shin T, Kraemer D, Pryor J, Liu L, Rugila J, Howe L, Buck S, Murphy
K, Lyons L and Westhusin M: A cat cloned by nuclear
transplantation. Nature 2002, 415:859.
10. Chesne P, Adenot PG, Viglietta C, Baratte M, Boulanger L and Renard
JP: Cloned rabbits produced by nuclear transfer from adult
somatic cells. Nat Biotechnol 2002, 20:366-369.
11. Woods GL, White KL, Vanderwall DK, Li GP, Aston KI, Bunch TD,
Meerdo LN and Pate BJ: A Mule Cloned from Fetal Cells by
Nuclear Transfer. Science 2003, 29:29.
12. Cibelli JB, Stice SL, Golueke PJ, Kane JJ, Jerry J, Blackwell C, Ponce de
Leon FA and Robl JM: Cloned transgenic calves produced from
nonquiescent fetal fibroblasts. Science 1998, 280:1256-1258.
13. McCreath KJ, Howcroft J, Campbell KH, Colman A, Schnieke AE and
Kind AJ: Production of gene-targeted sheep by nuclear trans-
fer from cultured somatic cells. Nature 2000, 405:1066-1069.
14. Lai L, Kolber-Simonds D, Park KW, Cheong HT, Greenstein JL, Im
GS, Samuel M, Bonk A, Rieke A and Day BN et al.: Production of
alpha-1,3-galactosyltransferase knockout pigs by nuclear
transfer cloning. Science 2002, 295:1089-1092.
15. Dai Y, Vaught TD, Boone J, Chen SH, Phelps CJ, Ball S, Monahan JA,
Jobst PM, McCreath KJ and Lamborn AE et al.: Targeted disruption
of the alpha 1,3-galactosyltransferase gene in cloned pigs. Nat
Biotechnol 2002, 20:251-255.
16. Welsh MJ, Tsui L-C, Boat TF and Beaudet AL: Cystic fibrosis. In: The
Metabolic Basis of Inherited Disease Edited by: Scriver CL, Beaudet AL, Sly
WS, Valle D. New York, McGraw-Hill; 1995:3799-3876. 
17. Davidson DJ and Rolfe M: Mouse models of cystic fibrosis. Trends
Genet 2001, 17:S29-37.
18. Grubb BR and Boucher RC: Pathophysiology of gene-targeted
mouse models for cystic fibrosis. Physiol Rev 1999, 79:S193-214.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/83
Page 8 of 8
(page number not for citation purposes)
19. Oldham MJ, Phalen RF and Huxtable RF: Growth of the ferret tra-
cheobronchial tree. Lab Anim Sci 1990, 40:186-191.
20. Leigh MW, Gambling TM, Carson JL, Collier AM, Wood RE and Boat
TF: Postnatal development of tracheal surface epithelium
and submucosal glands in the ferret.  Exp Lung Res 1986,
10:153-169.
21. Plopper CG, Hill LH and Mariassy AT: Ultrastructure of the non-
ciliated bronchiolar epithelial (Clara) cell of mammalian
lung. III. A study of man with comparison of 15 mammalian
species. Exp Lung Res 1980, 1:171-180.
22. Duan D, Sehgal A, Yao J and Engelhardt JF: Lef1 transcription fac-
tor expression defines airway progenitor cell targets for in
utero gene therapy of submucosal gland in cystic fibrosis. Am
J Respir Cell Mol Biol 1998, 18:750-758.
23. Kishioka C, Okamoto K, Kim J and Rubin BK: Regulation of secre-
tion from mucous and serous cells in the excised ferret
trachea. Respir Physiol 2001, 126:163-171.
24. Wang X, Zhang Y, Amberson A and Engelhardt JF: New models of
the tracheal airway define the glandular contribution to air-
way surface fluid and electrolyte composition. Am J Respir Cell
Mol Biol 2001, 24:195-202.
25. Sehgal A, Presente A and Engelhardt JF: Developmental expres-
sion patterns of CFTR in ferret tracheal surface airway and
submucosal gland epithelia.  Am J Respir Cell Mol Biol 1996,
15:122-131.
26. Engelhardt JF, Yankaskas JR, Ernst SA, Yang Y, Marino CR, Boucher
RC, Cohn JA and Wilson JM: Submucosal glands are the pre-
dominant site of CFTR expression in the human bronchus.
Nat Genet 1992, 2:240-248.
27. Fenton RJ, Morley PJ, Owens IJ, Gower D, Parry S, Crossman L and
Wong T: Chemoprophylaxis of influenza A virus infections,
with single doses of zanamivir, demonstrates that zanamivir
is cleared slowly from the respiratory tract. Antimicrob Agents
Chemother 1999, 43:2642-2647.
28. Leigh MW, Connor RJ, Kelm S, Baum LG and Paulson JC: Receptor
specificity of influenza virus influences severity of illness in
ferrets. Vaccine 1995, 13:1468-1473.
29. Collie MH, Rushton DI, Sweet C and Smith H: Studies of influenza
virus infection in newborn ferrets.  J Med Microbiol 1980,
13:561-571.
30. Jakeman KJ, Rushton DI, Smith H and Sweet C: Exacerbation of
bacterial toxicity to infant ferrets by influenza virus: possible
role in sudden infant death syndrome [published erratum
appears in J Infect Dis 1991 Jul;164(l):232]. J Infect Dis 1991,
163:35-40.
31. Husseini RH, Collie MH, Rushton DI, Sweet C and Smith H: The role
of naturally-acquired bacterial infection in influenza-related
death in neonatal ferrets. Br J Exp Pathol 1983, 64:559-569.
32. Kishioka C, Okamoto K, Hassett DJ, de Mello D and Rubin BK: Pseu-
domonas aeruginosa alginate is a potent secretagogue in the
isolated ferret trachea. Pediatr Pulmonol 1999, 27:174-179.
33. Li ZY, Jiang QS, Zhang YL, Liu XM and Engelhardt JF: Successful
production of offspring after superovulation and in vitro cul-
ture of embryos from domestic ferrets (Mustela putorius
furos). Reproduction 2001, 122:611-618.
34. Li Z, Jiang Q, Rezaei Sabet M, Zhang Y, Ritchie TC and Engelhardt JF:
Conditions for in vitro maturation and artificial activation of
ferret oocytes. Biol Reprod 2002, 66:1380-1386.
35. Li Z, Rezaei Sabet M, Zhou Q, Liu X, Ding W, Zhang Y, Renard JP and
Engelhardt JF: Developmental capacity of ferret embryos by
nuclear transfer using g0/g1-phase fetal fibroblasts. Biol Reprod
2003, 68:2297-2303.
36. Kidder JD, Giles JR, Foote RH, Richmond ME and Salerno M: Alloca-
tion of inner cell mass and trophectoderm cells to the pre-
implantation blastocyst of the domestic ferret, Mustela
putorius furo. J Exp Zool 1999, 283:202-209.
37. Santana E, Peritz AE, Iyer S, Uitto J and Yoon K: Different fre-
quency of gene targeting events by the RNA-DNA oligonu-
cleotide among epithelial cells.  J Invest Dermatol 1998,
111:1172-1177.
38. Xiang Y, Cole-Strauss A, Yoon K, Gryn J and Kmiec EB: Targeted
gene conversion in a mammalian CD34+-enriched cell popu-
lation using a chimeric RNA/DNA oligonucleotide. J Mol Med
1997, 75:829-835.
39. Cole-Strauss A, Yoon K, Xiang Y, Byrne BC, Rice MC, Gryn J, Hollo-
man WK and Kmiec EB: Correction of the mutation responsible
for sickle cell anemia by an RNA-DNA oligonucleotide. Sci-
ence 1996, 273:1386-1389.
40. Tran ND, Liu X, Yan Z, Abbote D, Jiang Q, Kmiec EB, Sigmund CD
and Engelhardt JF: Efficiency of chimeraplast gene targeting by
direct nuclear injection using a GFP recovery assay. Mol Ther
2003, 7:248-253.
41. Igoucheva O, Alexeev V and Yoon K: Targeted gene correction
by small single-stranded oligonucleotides in mammalian
cells. Gene Ther 2001, 8:391-399.
42. Yanagimachi R: Cloning: experience from the mouse and other
animals. Mol Cell Endocrinol 2002, 187:241-248.
43. Campbell KH, Loi P, Otaegui PJ and Wilmut I: Cell cycle co-ordina-
tion in embryo cloning by nuclear transfer. Rev Reprod 1996,
1:40-46.
44. Tani T, Kato Y and Tsunoda Y: Direct exposure of chromosomes
to nonactivated ovum cytoplasm is effective for bovine
somatic cell nucleus reprogramming.  Biol Reprod 2001,
64:324-330.
45. Ono Y, Shimozawa N, Ito M and Kono T: Cloned mice from fetal
fibroblast cells arrested at metaphase by a serial nuclear
transfer. Biol Reprod 2001, 64:44-50.
46. Zhou Q, Jouneau A, Brochard V, Adenot P and Renard JP: Develop-
mental potential of mouse embryos reconstructed from
metaphase embryonic stem cell nuclei.  Biol Reprod 2001,
65:412-419.
47. Kato Y, Tani T and Tsunoda Y: Cloning of calves from various
somatic cell types of male and female adult, newborn and
fetal cows. J Reprod Fertil 2000, 120:231-237.
48. Solter D: Mammalian cloning: advances and limitations. Nat
Rev Genet 2000, 1:199-207.
49. Fairburn HR, Young LE and Hendrich BD: Epigenetic reprogram-
ming: how now, cloned cow? Curr Biol 2002, 12:R68-70.
50. Han YM, Kang YK, Koo DB and Lee KK: Nuclear reprogramming
of cloned embryos produced in vitro.  Theriogenology 2003,
59:33-44.
51. Tsunoda Y and Kato Y: Full-term development after transfer of
nuclei from 4-cell and compacted morula stage embryos to
enucleated oocytes in the mouse. J Exp Zool 1997, 278:250-254.
52. Kato Y, Yabuuchi A, Motosugi N, Kato J and Tsunoda Y: Develop-
mental potential of mouse follicular epithelial cells and
cumulus cells after nuclear transfer.  Biol Reprod 1999,
61:1110-1114.
53. Wells DN, Misica PM and Tervit HR: Production of cloned calves
following nuclear transfer with cultured adult mural granu-
losa cells. Biol Reprod 1999, 60:996-1005.
54. Wakayama T, Rodriguez I, Perry AC, Yanagimachi R and Mombaerts
P: Mice cloned from embryonic stem cells. Proc Natl Acad Sci U
S A 1999, 96:14984-14989.
55. Rideout WM 3rd, Wakayama T, Wutz A, Eggan K, Jackson-Grusby L,
Dausman J, Yanagimachi R and Jaenisch R: Generation of mice
from wild-type and targeted ES cells by nuclear cloning. Nat
Genet 2000, 24:109-110.
56. Eggan K, Akutsu H, Loring J, Jackson-Grusby L, Klemm M, Rideout
WM 3rd, Yanagimachi R and Jaenisch R: Hybrid vigor, fetal over-
growth, and viability of mice derived by nuclear cloning and
tetraploid embryo complementation. Proc Natl Acad Sci U S A
2001, 98:6209-6214.